Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

Medizone Announces That Its AsepticSure(TM) Development Program Is Reaching Objectives On Two Fronts
Early results from the second series of trials have demonstrated a 5 log reduction (99.999%) in Pseudomonas aeruginousa and a 4.4 log reduction (99.994%) in Methicillin Resistant Staph Aureus (MRSA). Both of these pathogens are of major concern to medical treatment facilities world wide with the spread of MRSA infection often being referred to as the "silent epidemic". The CDC reported (JAMA 2007) that MRSA alone is now associated with an estimated 19,000 deaths annually in the US. Dr. Michael E. Shannon, Medizone"s Director of Medical Affairs commented, "Although the results from our first round of trials were very encouraging, introducing several procedural refinements in this second round resulted in levels of bactericidal action well above what was expected. Indeed, breaking through the 5 log barrier has led us to conclude that with a third technological development still to be introduced in this series of trials, the bactericidal ceiling for our system is now unclear, but well above what we ever expected. Needless to say, we are very excited over these findings and even more convinced that our new technologies will save hundreds of thousands of lives each year world wide. Add to the system"s efficacy the fact that it will be safe, extremely cost effective and adaptable to virtually any situation anywhere, leads me to conclude that AsepticSure will have a global reach."
generic viagra online
News From The Journals Of The American Society For Microbiology
"Single-Shot" Vaccines May Protect Against H5N1 Influenza Virus
News of the day
Echo-Location In Humans Developed By Spanish Scientists
A team of researchers from the University of Alcalá de Henares (UAH) has shown scientifically that human beings can develop echolocation, the system of acoustic signals used by dolphins and bats to explore their surroundings. Producing certain kinds of tongue clicks helps people to identify objects around them without needing to see them, something which would be especially useful for the blind.
Diagnostics

FDA Accepts CyDex Pharmaceuticals' IND Application For Oncology Drug

CyDex Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company"s Investigational New Drug (IND) application for a clinical study of Captisol-Enabled® melphalan HCL (CDX-353). Melphalan is an FDA-approved low dose chemotherapy for multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline. In December 2008, CyDex received orphan-drug designation from the FDA for melphalan "as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation." This designation provides an important economic incentive, granting CyDex seven years of exclusive marketing rights. "IND acceptance for Captisol-enabled melphalan is an important milestone for CyDex as we work to develop a portfolio of new drugs for the hospital acute care market," said Theron E. Odlaug, CyDex"s president and chief executive officer. "We look forward to establishing a relationship with a strategic out-licensing partner to advance CDX-353 into the clinic and, longer-term, develop and commercialize this promising oncology product." Upcoming clinical studies are expected to begin with a phase 2(a) trial that compares the pharmacokinetics of CyDex"s CDX-353: Propylene Glycol-Free Melphalan HCL with Alkeran, and evaluate safety parameters. Alkeran is packaged as two separate vials that must be combined prior to injection and, due to its limited stability, administered immediately thereafter. CyDex"s version of melphalan is enabled by Captisol®, the company"s proprietary and patented sulfobutylether í˛-cyclodextrin. Captisol-Enabled® melphalan is a one-vial formulation that does not contain harsh co-solvents and remains stable at room temperature for an extended period of time. "CDX-353 is a novel form of melphalan that is more stable and could potentially allow for longer administration durations and slower infusion rates compared to current pre-transplant treatments for multiple myeloma," said Parameswaran Hari, M.D., Clinical Director of the Adult Bone Marrow Transplant Program and Associate Professor of Medicine at the Medical College of Wisconsin. "These advantages have the potential to enable doctors to safely achieve a higher dose intensity of pre-transplant chemotherapy, which could lead to better therapeutic outcomes." CyDex Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009